ATP1A2
ENSG00000018625
Target class
Transporter
Chromosome
1
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- FHM2
- Target name
- ATP1A2
- Gene name
- ATPase Na+/K+ transporting subunit alpha 2
- Gene symbol
- ATP1A2
- Previous gene symbols
- MHP2
- Protein name
- Sodium/potassium-transporting ATPase subunit alpha-2 (Na(+)/K(+) ATPase alpha-2 subunit) (EC 7.2.2.13) (Sodium pump subunit alpha-2)
- Gene biotype
- Protein coding
- Gene family
- ATPase Na+/K+ transporting subunits
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 49
- Highest tissue expression
- 591.86
- Tissue specificity (Gini)
- 0.666
- Tissue specificity (tau)
- 0.815
- KEGG gene identifiers
- hsa:477
- Protein interaction confidence
- 0.8541
- Protein interaction partners
- 30
- R-HSA-5578775
- R-HSA-936837
- R-HSA-9679191
- End position
- 160143595
- Start position
- 160115758
- Chromosome
- 1
- Strand
- Forward
- Membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein .
Publication evidence
- PubMed 7711835
- Tissue specificity (tau)
- 0.81543
- Expression inequality (Gini)
- 0.665669
Expression in transcripts per million
- Muscle - Skeletal
- 591.86
- Brain - Caudate (basal ganglia)
- 555.44
- Brain - Cortex
- 492.31
- Brain - Nucleus accumbens (basal ganglia)
- 435.12
- Brain - Putamen (basal ganglia)
- 422.04
Expression in transcripts per million
- Muscle - Skeletal591.86
- Brain - Caudate (basal ganglia)555.44
- Brain - Cortex492.31
- Brain - Nucleus accumbens (basal ganglia)435.12
- Brain - Putamen (basal ganglia)422.04
- Brain - Anterior cingulate cortex (BA24)418.87
- Brain - Frontal Cortex (BA9)406.73
- Brain - Amygdala339.89
- Brain - Cerebellum302.9
- Brain - Substantia nigra259.15
- Nerve - Tibial243.9
- Brain - Hippocampus213.57
- Brain - Hypothalamus187.59
- Brain - Cerebellar Hemisphere161.99
- Artery - Tibial140.26
- Esophagus - Gastroesophageal Junction113.32
- Esophagus - Muscularis111.1
- Brain - Spinal cord (cervical c-1)103.65
- Colon - Sigmoid100.83
- Artery - Coronary94.48
- Artery - Aorta85.68
- Heart - Left Ventricle81.99
- Heart - Atrial Appendage80.5
- Adipose - Subcutaneous63.47
- Adipose - Visceral (Omentum)38.17
And 29 more, listed on the interactive page.
- GO:0006883
- GO:0010881
- GO:0030007
- GO:0035725
- GO:0036376
- GO:0046034
- GO:0055119
- GO:0060048
- GO:0071383
- GO:0071805
- GO:0086009
- GO:0086012
- GO:0086064
- GO:0098655
- GO:1903416
- GO:1990573
- GO:0005737
- GO:0005886
- GO:0005890
- GO:0016020
- GO:0030315
- GO:0031090
- GO:1903561
- GO:0005391
- GO:0005496
- GO:0005515
- GO:0005524
- GO:0016887
- GO:0019829
- GO:0030955
- GO:0031402
- GO:0051087
- GO:1990239
decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased heart rate
- renal
- cardiovascular
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- renal
- cardiovascular
PubMed 28216264atrioventricular block
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: atrioventricular block
- renal
- cardiovascular
PubMed 28216264vomiting
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: vomiting
- renal
- cardiovascular
PubMed 28216264increased cardiac contractility
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased cardiac contractility
- renal
- cardiovascular
PubMed 28216264cardiac arrhythmia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: cardiac arrhythmia
- renal
- cardiovascular
PubMed 28216264increased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- renal
- cardiovascular
PubMed 28216264ventricular fibrillation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: ventricular fibrillation
- renal
- cardiovascular
PubMed 28216264
Related records
Trials (335)
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- A Clinical Trial of Patients With Melanoma
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
- A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of ACH-0145228
- A Drug Interaction Study of Albiglutide and Digoxin
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
- A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
Drugs (6)
- Acetyldigitoxin Sodium/potassium-transporting ATPase inhibitor
- Deslanoside Sodium/potassium-transporting ATPase inhibitor
- Digitoxin Sodium/potassium-transporting ATPase inhibitor
- Digoxin Sodium/potassium-transporting ATPase inhibitor
- Istaroxime Sodium/potassium-transporting ATPase inhibitor
- Lanatoside C Sodium/potassium-transporting ATPase inhibitor